The therapeutic window of antibody drug conjugates: A dogma in need of revision
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference14 articles.
1. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer;Cortés;N. Engl. J. Med.,2022
2. Brain metastases in HER2-Positive breast cancer: current and novel treatment strategies;Garcia-Alvarez;Cancers,2021
3. Abstract GS3-01: trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03;Hurvitz;Cancer Res.,2022
4. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US Food and Drug Administration-approved antibody-drug conjugates?;Liao;Clin. Pharmacol. Ther.,2021
5. Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients;Lucas;Antibodies,2019
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Model‐informed dose selection for an investigational human epidermal growth factor receptor 2 antibody–drug conjugate FS‐1502 in patients with human epidermal growth factor receptor 2‐expressing advanced malignant solid tumours;British Journal of Clinical Pharmacology;2024-01-25
2. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer;Expert Opinion on Drug Metabolism & Toxicology;2024-01-12
3. Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET;mAbs;2024-01-12
4. Bispecific antibody drug conjugates: Making 1+1>2;Acta Pharmaceutica Sinica B;2024-01
5. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned;Journal of Hematology & Oncology;2023-12-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3